ALERS Eurobio Scientific Société anonyme
Eurobio Scientific Société anonyme engages in research, development, and marketing specialty diagnostic products in the areas of transplantation, infectious diseases, autoimmunity, oncology, and life sciences. The company produces and markets transport and preservation media for corneal grafts; AlloMap, for heart transplant follow up; cell culture media, molecular biology reagents, contract manufacturing service, and proprietary antibodies; TQS (Tetanus Quick Stick), a rapid test used in emergency departments or pharmacies to assess the vaccination status or immune protection of patients against tetanus; EBX molecular biology ranges in the field of infectious diseases; and EndoPredict range, a second-generation multigene expression test for postmenopausal women with early-stage breast cancer, ER positive, and HER2 negative, as well as Prolaris. It also provides GenDx, EurobioPlex, FungiLine, Biosafety PKA, and immunology products. The company was formerly known as Diaxonhit and changed its name to Eurobio Scientific Société anonyme in June 2018. Eurobio Scientific Société anonyme was incorporated in 1997 and is headquartered in Les Ulis, France.…
Industry Peers
Medical DevicesKey Statistics
About Eurobio Scientific (EPA: ALERS)
›
Eurobio Scientific (EPA: ALERS) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 443 employees.
The shares were at 26.40 EUR on 19 November 2026, up 8.2% over 52 weeks. Its 52-week range is 19.20 EUR to 26.55 EUR, and it trades at the top of that range.
At a market capitalisation of 265.80M EUR, it trades at 37.7 times trailing earnings and 23.4 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, a premium of 47% for ALERS.
Eurobio Scientific reports return on equity of 2.6%, an operating margin of 7.8% and revenue up 4.5% year over year.
It holds more cash than debt, a net cash position of 11.60M EUR. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. One analyst covers the stock; their mean price target of 30.00 EUR is 13.6% above the current price.